MCOPPB triHydrochloride (Synonyms: MCOPPB 3HCl) |
Katalog-Nr.GC36562 |
MCOPPB 3Hcl ist ein Nociceptin-Rezeptoragonist mit einem pKi von 10,07; schwÄchere AktivitÄt an anderen Opioidrezeptoren.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1108147-88-1
Sample solution is provided at 25 µL, 10mM.
MCOPPB 3Hcl is a nociceptin receptor agonist with pKi of 10.07; weaker activity at other opioid receptors.IC50 value: 10.07 (pKi)Target: nociceptin receptorMCOPPB trihydrochloride is a trihydrochloride form of MCOPPB that is a new nonpeptide nociceptin/orphanin FQ peptide (NOP)-receptor agonist with a pKi of 10.07 ± 0.01 for the human NOP receptor.
[1]. Hayashi, Shigeo; Hirao, Akiko; Imai, Aki; Nakamura, Hiroshi; Murata, Yoshinori; Ohashi, Katsuyo; Nakata, Eriko. Novel Non-Peptide Nociceptin/Orphanin FQ Receptor Agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: Design, Synthesis, and Structure-Activity Relationship of Oral Receptor Occupancy in the Brain for Orally Potent Antianxiety Drug. Journal of Medicinal Chemistry (2009), 52(3), 610-625. [2]. Hayashi S, Hirao A, Imai A, Nakamura H, Murata Y, Ohashi K, Nakata E.Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug.J Med Chem. 2009 Feb 12;52(3):610-25. [3]. Hirao A, Imai A, Sugie Y, Yamada Y, Hayashi S, Toide K.Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent.J Pharmacol Sci. 2008 Mar;106(3):361-8. Epub 2008 Mar 5.
Average Rating: 5
(Based on Reviews and 18 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *